Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 6Sarcoma 5Liposarcoma 4Leiomyosarcoma 3Neoplasms 2Fallopian Tube Neoplasms 2Sarcoma, Ewing 1Recurrent High Grade Meningioma 1Recurrence 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm Metastasis 1Liposarcoma, Myxoid 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Paclitaxel 57Carboplatin 51Bevacizumab 41Taxes 28liposomal doxorubicin 21Gemcitabine 19Immunoglobulin G 17Disulfides 17pembrolizumab 15Topotecan 12rucaparib 10Cyclophosphamide 9Cisplatin 9Docetaxel 8olaparib 7Doxorubicin 7pazopanib 6mirvetuximab soravtansine 6cediranib 6Nivolumab 6Magnetic Resonance Spectroscopy 6Specimen Handling 5sargramostim 4niraparib 4Surgical Procedures, Operative 4Drug Therapy 4Cytoreduction Surgical Procedures 4Albumin-Bound Paclitaxel 4veliparib 3fludarabine phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Fallopian Tube Neoplasms × Trabectedin × Clear all
NCT01846611 2019-04-01

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Janssen Research & Development, LLC

Phase 3 Completed
581 enrolled 14 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00569673 2018-07-18

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

GOG Foundation

Phase 2 Completed
71 enrolled 8 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡